87 related articles for article (PubMed ID: 15172758)
1. Parental 19q loss and PEG3 expression in oligodendrogliomas.
Trouillard O; Aguirre-Cruz L; Hoang-Xuan K; Marie Y; Delattre JY; Sanson M
Cancer Genet Cytogenet; 2004 Jun; 151(2):182-3. PubMed ID: 15172758
[No Abstract] [Full Text] [Related]
2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas.
Yang P; Kollmeyer TM; Buckner K; Bamlet W; Ballman KV; Jenkins RB
Cancer; 2005 Jun; 103(11):2363-72. PubMed ID: 15834925
[TBL] [Abstract][Full Text] [Related]
4. No preferential loss of paternal 19q alleles in oligodendroglial tumors.
Hartmann C; Mueller W; Lass U; Stockhammer F; von Eckardstein K; Veelken J; Jeuken J; Wick W; von Deimling A
Ann Neurol; 2003 Aug; 54(2):256-8. PubMed ID: 12891681
[TBL] [Abstract][Full Text] [Related]
5. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.
Griffin CA; Burger P; Morsberger L; Yonescu R; Swierczynski S; Weingart JD; Murphy KM
J Neuropathol Exp Neurol; 2006 Oct; 65(10):988-94. PubMed ID: 17021403
[TBL] [Abstract][Full Text] [Related]
6. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
Cairncross G; Jenkins R
Cancer J; 2008; 14(6):352-7. PubMed ID: 19060598
[TBL] [Abstract][Full Text] [Related]
7. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.
Sonabend AM; Lesniak MS
Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S25-32. PubMed ID: 16274268
[TBL] [Abstract][Full Text] [Related]
8. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas.
Kitange G; Misra A; Law M; Passe S; Kollmeyer TM; Maurer M; Ballman K; Feuerstein BG; Jenkins RB
Genes Chromosomes Cancer; 2005 Jan; 42(1):68-77. PubMed ID: 15472895
[TBL] [Abstract][Full Text] [Related]
9. Imaging correlates of molecular signatures in oligodendrogliomas.
Megyesi JF; Kachur E; Lee DH; Zlatescu MC; Betensky RA; Forsyth PA; Okada Y; Sasaki H; Mizoguchi M; Louis DN; Cairncross JG
Clin Cancer Res; 2004 Jul; 10(13):4303-6. PubMed ID: 15240515
[TBL] [Abstract][Full Text] [Related]
10. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas.
Kreiger PA; Okada Y; Simon S; Rorke LB; Louis DN; Golden JA
Acta Neuropathol; 2005 Apr; 109(4):387-92. PubMed ID: 15739101
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
[TBL] [Abstract][Full Text] [Related]
12. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
Gadji M; Fortin D; Tsanaclis AM; Drouin R
Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649
[TBL] [Abstract][Full Text] [Related]
13. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
[TBL] [Abstract][Full Text] [Related]
14. [The oligodendroglioma: the value of histologic and genetic diagnosis in predicting sensitivity to chemotherapy].
Kros JM
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1379-85. PubMed ID: 15997690
[TBL] [Abstract][Full Text] [Related]
15. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.
Franco-Hernández C; Martínez-Glez V; de Campos JM; Isla A; Vaquero J; Gutiérrez M; Casartelli C; Rey JA
Cancer Genet Cytogenet; 2009 Apr; 190(2):93-6. PubMed ID: 19380026
[TBL] [Abstract][Full Text] [Related]
16. Oligodendroglioma with neurocytic differentiation and characteristic loss of heterozygosity on chromosomes 1p and 19q.
Vajtai I; Arnold M; Vassella E
Acta Neuropathol; 2005 Nov; 110(5):520-2. PubMed ID: 16222523
[No Abstract] [Full Text] [Related]
17. Chromosome 1p loss evaluation in anaplastic oligodendrogliomas.
Idbaih A; Kouwenhoven M; Jeuken J; Carpentier C; Gorlia T; Kros JM; French P; Teepen JL; Delattre O; Delattre JY; van den Bent M; Hoang-Xuan K
Neuropathology; 2008 Aug; 28(4):440-3. PubMed ID: 18312547
[TBL] [Abstract][Full Text] [Related]
18. [Loss of heterozygosity on chromosomes 1 and 19 in cases of primary brain tumour].
Born PW; Broholm H; Laursen H
Ugeskr Laeger; 2006 Oct; 168(44):3813-6. PubMed ID: 17118240
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of PEG3 gene expression in human glioma cell lines.
Maegawa S; Yoshioka H; Itaba N; Kubota N; Nishihara S; Shirayoshi Y; Nanba E; Oshimura M
Mol Carcinog; 2001 May; 31(1):1-9. PubMed ID: 11398192
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T
Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
